Business Wire

Mary Kay Inc. Names Dr. Lucy Gildea Chief Brand and Scientific Officer

Share

To empower future growth, iconic beauty and entrepreneurship company Mary Kay Inc. announced today the appointment of Dr. Lucy Gildea as Chief Brand and Scientific Officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250206167665/en/

Mary Kay Inc. Names Dr. Lucy Gildea Chief Brand and Scientific Officer. Gildea and her freshly designed cross-functional team will pioneer a new operating model to power up Mary Kay’s global brand and science aiming for growth and customer loyalty in over 40 markets. (Photo: Mary Kay Inc.)

Gildea and her freshly designed cross-functional team will pioneer a new operating model to power up Mary Kay’s global brand and science aiming for growth and customer loyalty in over 40 markets. In her expanded role, Gildea will shape a powerful brand identity, image, and strategy consistent across all platforms and geographies supported by an impactful product portfolio embracing the ever-evolving needs of consumers. She and her team will activate the brand through engagement strategies harnessing the power of next-gen entrepreneurs and resonant brand storytelling to win the hearts and minds of consumers.

"With her expertise in science and beauty innovation and customer-centric approach, Lucy will lead a strategic chapter of our transformation into the future. The new Global Brand and Science organization will contribute to our mutual business success by enabling our Independent Beauty Consultants to share a transformative brand experience with their customers and thrive as personal beauty advisors, thus reinforcing the unique value proposition of direct selling," said Ryan Rogers, Chief Executive Officer of Mary Kay and grandson of Mary Kay Ash.

Since joining Mary Kay in 2017, Gildea has focused on modernizing and enhancing the company's competitiveness through product innovation and by improving organizational efficiencies. Gildea spent 15 years at Procter & Gamble working primarily in beauty technology and beauty/skin product development. She also held a variety of senior roles including leading development teams for upstream technology and measurement sciences across healthcare, beauty and personal care industries. During her tenure at P&G, Gildea lived in Singapore, advancing her experience with international markets.

"Mary Kay was founded on a dream to enrich women’s lives with a product portfolio rooted in science. I am confident that integrating brand and science is the winning formula to meet global consumer needs and work toward our continued success. I look forward to maximizing synergies across our teams to captivate our Independent Beauty Consultants and invite a new generation of consumers to fall in love with our brand," said Dr. Lucy Gildea, Mary Kay’s Chief Brand and Scientific Officer.

Gildea earned a Ph.D. in Cell and Molecular Biology, Immunology, and Infectious Diseases at the University of Cincinnati College of Medicine and a Postdoctoral Research Fellowship in Immunology in a joint appointment with Cincinnati Children’s Hospital and the University of Cincinnati Department of Immunology. She also holds a Bachelor of Science in Biology from Georgetown College in Georgetown, Kentucky.

Gildea is a passionate STEM advocate for women and girls. She serves as a Board Member at Baylor Scott & White Dallas Foundation and a Board Advisor at Baylor Scott & White Charles A. Sammons Cancer Center.

This leadership appointment by Ryan Rogers honors Mary Kay Ash’s legacy of empowering women. At Mary Kay, women make up 63% of the R&D team, 54% of the executive team, and 63% of the global workforce1.

Did you know:

  • In 2023 and again in 2024, Mary Kay was named the #1 Direct Selling brand of skin care & color cosmetics in the world by Euromonitor International2.
  • Mary Kay holds more than 1,600 patents for products, technologies, and packaging designs in its global portfolio3.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of Independent Beauty Consultants in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on X.

_______________________
1 Source: Women Representation and Leadership at Mary Kay (May 2024).
2 “Source Euromonitor International Limited; Beauty and Personal Care 2024 Edition, value sales at RSP, 2023 data”
3 As of 2023.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250206167665/en/

Contacts

Mary Kay Inc. Corporate Communications
marykay.com/newsroom -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnewsroom.maryk
ay.com%2F&esheet=54201083&newsitemid=20250206167665&lan=en-US&anchor=marykay.com
%2Fnewsroom&index=9&md5=54f905d7ab8fe599beea511210787de9
972.687.5332 or media@mkcorp.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release

The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th

Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release

Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor

Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release

Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to

I-care Becomes a Unicorn23.12.2025 10:45:00 CET | Press Release

I-care announces the completion of a €20 million fundraising and refinancing operation, carried out as a round reserved for existing shareholders and employees. Based on this operation, the group's valuation reaches €1 billion, making I-care a unicorn. "Becoming a unicorn is a symbolic milestone. To achieve this, we chose to invest before reaping the rewards: we bet on AI when few believed in it, we prioritized R&D, and we built our own production unit. These choices were sometimes difficult, but they were essential to staying ahead of the game. Today, our results confirm that this strategy was the right one," explains Fabrice Brion, CEO of I-care. This fundraising round is the first step in a three-phase development plan. Following the “Eau Rouge” operation in 2022, which enabled I-care to become the world leader in predictive maintenance, the company has now set itself a clear objective: to accelerate its growth in order to increase its market share. The second phase of this plan wil

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye